Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

CAM2029

Aliases
CAM2029 (octreotide subcutaneous depot), octreotide subcutaneous depot
Name
Mycapssa
INN Name
OCTREOTIDE ACETATE
FDA Approved
Yes

4 clinical trials

3 organizations

3 indications

2 documents

Indication
Gastroenteropancreatic Neuroendocrine Tumor
Indication
Polycystic Liver Disease
Indication
Acromegaly
Clinical trial
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
Status: Completed, Estimated PCD: 2023-05-02
Document
DailyMed Label: Mycapssa
Organization
Chiesi USA, Inc.
Organization
Amryt Pharmaceuticals Designated Activity Company
Document
DailyMed Label: Octreotide
Organization
Fresenius Kabi USA, LLC